Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10385
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFealy, Nigel Gen
dc.contributor.authorBaldwin, Ian Cen
dc.contributor.authorJohnstone, Men
dc.contributor.authorEgi, Moritokien
dc.contributor.authorBellomo, Rinaldoen
dc.date.accessioned2015-05-15T23:49:11Z
dc.date.available2015-05-15T23:49:11Z
dc.date.issued2007-04-01en
dc.identifier.citationThe International Journal of Artificial Organs; 30(4): 301-7en
dc.identifier.govdoc17520566en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10385en
dc.description.abstractTo evaluate the efficacy and safety of a regional heparinization and a regional citrate method of anticoagulation in CVVH.Randomized controlled cross-over study.Ten critically ill patients with acute renal failure.ICU of tertiary hospital.CVVH was performed with pre-filter fluid replacement at 2000 ml/h and a blood flow rate of 150 ml/min. Regional heparinization was by the administration of heparin pre-filter at 1500 IU/h and protamine post-filter at 15 mg/h. Regional citrate anticoagulation was by means of a citrate-based replacement fluid (14 mmol/L) administered pre-dilution.We studied nine males and one female. The mean age and APACHE II score were 70.5 and 17 respectively. Median circuit life was 13 hours (IQR 9.28) for the regional heparinization method compared to 17 hours (IQR 12,19.5) for the regional citrate method (p=0.77). There were no episodes of bleeding in either group.Regional heparinization and regional citrate anticoagulation achieve similar circuit life in critically ill patients receiving CVVH.en
dc.language.isoenen
dc.subject.otherAcute Kidney Injury.therapyen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAnticoagulants.therapeutic useen
dc.subject.otherCalcium.therapeutic useen
dc.subject.otherCitric Acid.therapeutic useen
dc.subject.otherCross-Over Studiesen
dc.subject.otherFemaleen
dc.subject.otherHemodialysis Solutions.therapeutic useen
dc.subject.otherHemofiltration.methodsen
dc.subject.otherHeparin.therapeutic useen
dc.subject.otherHeparin Antagonists.therapeutic useen
dc.subject.otherHumansen
dc.subject.otherIntensive Careen
dc.subject.otherMagnesium.therapeutic useen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPilot Projectsen
dc.subject.otherProtamines.therapeutic useen
dc.subject.otherSafetyen
dc.subject.otherTime Factorsen
dc.subject.otherTreatment Outcomeen
dc.titleA pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration.en
dc.typeJournal Articleen
dc.identifier.journaltitleInternational Journal of Artificial Organsen
dc.identifier.affiliationDepartment of Intensive Care, Austin Hospital, Melbourne - Australiaen
dc.description.pages301-7en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/17520566en
dc.type.austinJournal Articleen
local.name.researcherBaldwin, Ian C
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptIntensive Care-
crisitem.author.deptIntensive Care-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Nov 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.